Notice about cookies

Close

This website uses a limited number of cookies to improve your browsing experience. For further information (including how to withdraw consent), please refer to our Cookie Policy. By clicking Accept below or continuing to use this website (including closing this message), you confirm that you have read and consent to our use of cookies as detailed in our Cookie Policy.

Accept

UCB's Global Corporate Website
Welcome to UCB in the United States

Categories

Archives

Feb

04

UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

Read More Share:linkedin| twitter| email

Jan

21

Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

Read More Share:linkedin| twitter| email

Jan

19

UCB to acquire Zogenix

Read More Share:linkedin| twitter| email

Dec

16

Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

Read More Share:linkedin| twitter| email

Dec

10

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Read More Share:linkedin| twitter| email

Dec

03

UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021, reinforcing long-standing commitment to advancing epilepsy treatment and care

Read More Share:linkedin| twitter| email

Nov

19

Positive Top-Line Results from Bimekizumab Phase 3 Psoriatic Arthritis Study Demonstrated Significant Improvements in Joint and Skin Symptoms

Read More Share:linkedin| twitter| email

Oct

22

UCB Presents Number Needed to Treat Analysis for Bimekizumab in Moderate to Severe Plaque Psoriasis at AMCP Nexus

UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21. 

Read More Share:linkedin| twitter| email

Aug

30

UCB Announces BRIVIACT® (brivaracetam) CV Now FDA-Approved to Treat Partial-Onset Seizures in Pediatric Patients One Month of Age and Older

Read More Share:linkedin| twitter| email

Aug

07

New Two-Year Data Showed Bimekizumab Maintained High Levels of Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis

Read More Share:linkedin| twitter| email

© 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
USPR-CORP-0115-00003(2)